Considering recombinant herpes zoster vaccine for fragile pediatric patients: A new opportunity
In our cohort, many cases had comorbidities contraindicating the live attenuated vaccine. If proven safe and effective, the recombinant HZ vaccine could offer a preventive option for immunocompromised children ineligible for live viral vaccines.
Authors
- Giuseppe Indolfi (ORCID: https://orcid.org/0000-0003-3830-9823)
- Iacopo Sardi (ORCID: https://orcid.org/0000-0002-8763-6524)
- Annalisa Tondo (ORCID: https://orcid.org/0000-0003-2784-5487)
- Paolo Lionetti (ORCID: https://orcid.org/0000-0001-8029-3904)
- Lorenzo Lodi (ORCID: https://orcid.org/0000-0001-6902-544X)
- Antonio Mollo (ORCID: https://orcid.org/0000-0002-6828-6389)
- Marta Peri (ORCID: https://orcid.org/0000-0002-2786-0292)
- Elisabetta Venturini (ORCID: https://orcid.org/0000-0002-0048-3933)
- Maria Vincenza Mastrolia (ORCID: https://orcid.org/0000-0002-9784-3543)
- Sandra Trapani (ORCID: https://orcid.org/0000-0003-1105-1500)
- Valeria Astorino
- Luisa Galli (ORCID: https://orcid.org/0000-0002-7912-3366)
- Anna Gissi
- Veronica Tintori
- C. Azzari
- Edoardo Marrani (ORCID: https://orcid.org/0000-0002-0346-3268)
- Silvia Ricci
Institutions
- Meyer Children's Hospital (IT)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
- University of Florence (IT)
Publication Details
- Journal
- Vaccine
- Published
- 2025-04-01
- DOI
- https://doi.org/10.1016/j.vaccine.2025.127072
- Primary Topic
- Herpesvirus Infections and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- European Commission